

Adina M Hughes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5129780/publications.pdf>

Version: 2024-02-01

10
papers

511
citations

1478505

6
h-index

1720034

7
g-index

10
all docs

10
docs citations

10
times ranked

1010
citing authors

#	ARTICLE	IF	CITATIONS
1	ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib. <i>Cancer Research</i> , 2022, 82, 1140-1152.	0.9	52
2	Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer. , 2022, 10, e003892.		26
3	Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3K β Inhibition. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1080-1091.	4.1	7
4	Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 13-25.	4.1	104
5	<i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1. <i>Clinical Cancer Research</i> , 2020, 26, 6335-6349.	7.0	26
6	Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 909-919.	4.1	13
7	Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery. , 2019, 7, 328.		65
8	Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. <i>Oncotimmunology</i> , 2018, 7, e1458810.	4.6	30
9	PI3K β inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity. , 2018, 6, 158.		62
10	The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5153-5164.	7.0	126